Thank you for your comments! IVI has released all public feedback received during the open comment period for the IVI-NSCLC model - our open-source platform to assess therapy sequences for EGFR+ non-small cell lung cancer. In the spirit of IVI's mission of collaboration, commitment to transparency, and dedication to iterative improvement, we look forward to [...]
In the wake of this year's ISPOR conference, IVI's Executive Director, Jennifer Bright, reflects on how to move value assessment from a static snapshot in time to an active learning approach. She discusses the following five steps to improving value assessment: Take the transparency challenge. Embrace flexibility. Allow for iteration. Improve incorporation of non-clinical data. [...]
Heard at ISPOR: Wide Ranging Podcast with IVI on Advanced Value Assessment Methods and the QALY Controversy
The IVI team sat down with the Journal of Clinical Pathways while at ISPOR for an in-depth discussion about why advanced value assessment is needed and how it’s progressing. The team also discussed the QALY – what it is and whether it can be improved. To listen to the podcast or read the transcript, click [...]
As part of the public input process, IVI submitted comments on the Institute for Clinical and Economic Review’s (ICER) 2020 Value Assessment Framework. In May, ICER invited public comments as part of their process to update methods that underpin ICER reports. In summary, IVI wrote that value assessment must: • Provide flexible models that can [...]
After the panel presentation, “The Controversial QALY: Is There a Middle Ground in the Debate?” was wrapped up at ISPOR, AJMC deputy editor, Jaime Rosenberg, sat down with IVI's Jennifer Bright and Lou Garrison (assistant director of the Pharmaceutical Outcomes Research and Policy Program at the University of Washington) to drill down further into the [...]
IVI Executive Director, Jennifer Bright, moderated a fascinating panel discussion on the quality-adjusted life-year (QALY) and whether there is room for a middle ground in the discussion about its merits and shortcomings. Lou Garrison, PhD, Assistant Director of the Pharmaceutical Outcomes Research and Policy Program at the University of Washington; Eleanor M. Perfetto, PhD, MS, [...]
IVI launches a new research brief series to present research findings and method insights from the OSVP. Let’s sparks a conversation into next-gen value assessment. Read the full press release here.
IVI is committed to exploring scientifically rigorous methods that improve the practice of value assessment in a collaborative, iterative environment. To that end, we are pleased to announce the call for research proposals that help us advance our mission and demonstrate the applicability of patient-defined factors of value. IVI welcomes proposals from individual researchers as [...]
IVI's Lead Scientific Advisor and Lead Economist for the Open-Source Value Platform (OSVP), Jeroen Jansen and Devin Incerti, respectively, collaborate with Jeffery Curtis in a recent article published in the Journal of Managed Care and Specialty Pharmacy about how IVI’s open-source approach to value assessment provides a way to adapt formal assessments of value—long the [...]
IVI Executive Director, Jennifer Bright, writes in Morning Consult about the differences between patient-centered and consumer-driven healthcare. Read the full article here.